Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

(18)F-FDG-PET and PET/CT for Evaluating Primary Bone Tumors. PET clinics Mittra, E., Iagaru, A. 2010; 5 (3): 327-339

Abstract

Imaging is critical for the proper evaluation of patients with primary tumors of bone. There is a growing role for (18)F-fluorodeoxyglucose PET and PET/computed tomography (CT) in the grading, staging, prognostication, evaluation of therapeutic response, and detection of recurrent disease in bone. These modalities can also be used to help differentiate benign from malignant disorders of bone.

View details for DOI 10.1016/j.cpet.2010.04.004

View details for PubMedID 27157837